TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS	iii
ABSTRACT (in English)	v
ABSTRACT (in Thai)	vii
TABLE OF CONTENTS	ix
LIST OF TABLES	xiv
LIST OF FIGUES	XV
ABBREVIATIONS	xviii
CHAPTER I INTRODUCTION	1
CHAPTER II LITERATURE REVIEWS	6
1. Survivin gene	7
2. Expression characteristics of survivin	7
3. Survivin as a tumor marker	e_8^{0}
4. Livin gene	9
5. Expression characteristics of livin	10
6. Livin as a tumor marker	10

ix

		Page
7.	Auto-antibody: a potential ideal tumor marker	11
CH	IAPTER III OBJECTIVES	14
CH	IAPTER IV MATERIALS AND METHODS	15
1.	Detection of expression level of livin and survivin in tumor tissues	15
	with Western blot Analysis	
	1.1 Population of the study	15
	1.2 Preparation of cell lysate	15
	1.3 Protein assay	16
	1.4 Separation of protein by sodium dodecyl sulfate-	17
	polyacrylamide gel electrophoresis (SDS-PAGE)	
	1.5 Electrotransfer of separated proteins from the gel into	18
	the membrane	
	1.6 Immunoblotting process	18
2.	Detection of autoantibodies against livin and survivin in	19
	lung cancer patients	
	2.1 Production of recombinant livin and survivin tumor antigens	19
	2.1.1 Construction of expression vector	19
	2.1.1.1 Preparation of livin and survivin encoding DNA	23
	for insertion into pET-15b vector	
	2.1.1.2 Digestion of pET-15b vector and NdeI-livin-BamHI	25
	PCR product, NdeI-survivin-BamHI PCR product	
	with restriction enzymes	

Page

2.1.1.3 Ligation	26
2.1.1.4 Transformation of competent cells	26
2.1.1.5 Positive clones screening	27
2.1.1.6 Growth of the correct transformant in liquid media	27
and storage	
2.1.2 Expression of livin and survivin recombinant proteins	28
in bacterial host cells	
2.1.2.1 Determination of the level of expressed protein	28
2.2 Optimization of ELISA	29
2.2.1 Finding optimal antigen concentration	30
2.2.2 Finding optimal coating buffer	31
2.2.3 Finding optimal blocking agent	31
2.2.4 Finding optimal serum dilution	31
2.3 Evaluation of the established ELISA	32
2.3.1 Reproducibility testing of the established ELISA	32
2.3.2 Verification of autoantibody specificity by	33
pre-absorption experiment	
2.3.2.1 Purification of $(His)_6$ -survivin protein by	33
His-Bind Resin chromatography	
2.3.2.2 Pre-absorption of samples with recombinant survivin	35
2.4 Detection of livin and survivin specific autoantibodies	35
in lung cancer patient serum using the generated (His) ₆ -livin	
and survivin proteins	

	1 450
2.5 Statistical analysis	35
CHAPTER V RESULTS	36
1. Detection of expression level of livin and survivin in tumor tissues	36
and normal tissues with Western blot analysis	
2. Detection of autoantibodies against livin and survivin in	39
lung cancer patients	
2.1 Production of recombinant livin and survivin tumor antigens	39
2.1.1 Construction of expression vectors (pET-15b-livin and	39
pET-15b-survivin)	
2.1.2 Expression of livin and survivin recombinant proteins	46
in bacterial host cells	
2.2 Optimization of ELISA	49
2.2.1 Optimization of antigen concentration	49
2.2.2 Optimization of coating buffer for coating $(His)_6$ -livin	52
and (His) ₆ -survivin antigens onto a microtiter plate	
2.2.3 Optimization of blocking agent	55
2.2.4 Optimization of serum dilution	58
2.3 Evaluation of the established ELISA	60
2.3.1 Reproducibility study of the established ELISA	60
2.3.2 Verification of autoantibody specificity by	63
pre-absorption experiment	
2.3.2.1 Purification of (His) ₆ -survivin protein	63

Page

	Page
2.3.2.2 Pre-absorption of anti-survivin antibody with	65
purified (His) ₆ -survivin protein	
2.4 Detection of livin and survivin autoantibodies in	67
lung cancer patient serum using the generated (His) ₆ -livin	
and (His) ₆ -survivin proteins	
2.5 Correlations between anti-livin, anti-survivin antibodies	69
positivity and clinicopathologic features	
CHAPTER VI DISCUSSION	70
CHAPTER VII CONCLUSION	76
REFERENCES	78
APPENDICES	90
CURRICULUM VITAE	99

LIST OF TABLES

Table

Page

- 1 Clinicopathologic features of lung tumor samples investigated
 37

 in this study (n=52)
 37
- 2 Correlations of anti-livin and anti-survivin antibodies levels upon
 69 diagnosis with clinicopathological parameters in all patients (n=42)

LIST OF FIGURES

Figure

Page

1	Representative western blot analysis of cell lysates	38
	(T = tumor tissue and N = normal tissue) from lung cancer patients.	
2	Agarose gel analysis showing the obtained livin PCR products using	42
	NdeIlivin and livinBamHI as primers.	
3	Agarose gel analysis showing the obtained survivin PCR products	42
	using NdeIsurvivin and survivinBamHI as primers.	
4	An example of agarose gel analysis of PCR products to verify the	43
	appropriate ligation between pET-15b vector and livin DNA in	
	ligation mixture.	
5	An example of agarose gel analysis of PCR products to verify	43
	the appropriate ligation between pET-15b vector and suvivin DNA	
	in ligation mixture.	
6	Agarose gel analysis of antibiotic resistant colonies screening for	44
	pET-15b-livin vector uptaking clone by PCR.	
7	Agarose gel analysis of antibiotic resistant colonies screening for	44
	pET-15b-survivin vector uptaking clone by PCR.	
8	Agarose gel analysis of restriction enzyme digested products to	45
	confirm the obtained positive colony of livin.	

XV

Figure		
9 Agarose gel analysis of restriction enzyme digested products to	45	
confirm the obtained positive colonies of survivin.		
10 Western blot analysis of hexahistidine-livin fusion protein	47	
express in <i>E.coli</i> DE3 and DE3pLysS cells using		
anti-histidine mAb and anti-livin mAb.		
11 Western blot analysis of hexahistidine-survivin fusion protein	48	
express in <i>E.coli</i> DE3 and DE3pLysS cells using		
anti-histidine mAb and anti-survivin mAb.		
12 Optimization of the concentration of His ₆ -livin antigen to be	50	
coated onto an ELISA plate.		
13 Optimization of the concentration of His ₆ -survivin antigen to be	51	
coated onto an ELISA plate.		
14 Finding the most suitable buffer for coating (His) ₆ -livin antigen	53	
onto microtiter plate.		
15 Finding the most suitable buffer for coating (His) ₆ -survivin antig	gen 54	
onto microtiter plate.		
16 Finding the most suitable blocking agent for detection of	56	
anti-livin autoantibody.		
17 Finding the most suitable blocking agent for detection of	57	
anti-survivin autoantibody.		
18 Finding the most suitable serum dilution for detection of anti-livi	in 59	

and anti-survivin antibodies.

Figure		
19	The quality control chart of livin's OD of the control serum by	61
	established ELISA.	
20	The quality control chart of survivin's OD of the control serum	62
	by established ELISA.	
21	Coomassie blue stain of polyacrylamide gel showing preliminary	64
	purification process of His ₆ -survivin fusion protein using affinity	
	chromatography.	
22	Pre-absorption of anti-survivin mAb and sera from lung cancer	66
	patients with purified recombinant survivin protein.	
23	Detection of antibodies response to livin and survivin by	68
	established ELISA.	

ABBREVIATIONS AND SYMBOLS

bp	base pair
cDNA	complementary DNA
°C	degree Celsius
CV	coefficient of variation
DNA	deoxyribonucleic acid
ECL	enhanced chemiluminescence
g	gram
HC1	hydrochloride
His	histidine
(His) ₆ -livin	hexahistidine tagged livin
(His) ₆ -survivin	hexahistidine tagged
survivin	
IgG	immunoglobulin G
เห็กริบหาวิทยาส	kilobase
kDa	kilo-Dalton
pyright [©] by Chiang	litre University
m rights r	Cmililitre C C C
mM	millimolar
mRNA	messenger RNA
Μ	molar

xviii

xix

nm	nanometer
NaCl	sodium chloride
NaOH NaOH	sodium hydroxide
OD OD	optical density
PBS	phosphate-buffered saline
rpm	revolution per minute
RNA	ribonucleic acid
SD	standard deviation
SDS	sodium dodesyl sulfate
SDS-PAGE	sodium dodesyl sulfate-
	polyacrylamide gel
	electrophoresis
TEMED	N,N,N',N'-tetramethylethyllene
	diamine
Tris	tris(hydroxymethyl)
	aminomethane
Tris-HCl	tris(hydroxymethyl)
	aminomethane hydrochloride
^µ rights r	microlitre
μg	microgram
α	alpha
β	beta
(v/v)	volume: volume ratio

